Lymphangiomyomatosis (LAM) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Lymphangioleiomyomatosis (LAM) is a condition that affects the lungs, the kidneys, and the lymphatic system of women during childbearing age. Etiology- Mutations in the TSC1 gene or, more commonly, the TSC2 gene, cause LAM. Epidemiology- It is estimated to affect 3.3 to 7.4 per million women worldwide. The competitive landscape of Lymphangiomyomatosis (LAM) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Lymphangiomyomatosis (LAM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. Lymphangiomyomatosis (LAM) Market Forecast : Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with...